8/19/2013 7:52:32 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Cigna Corp. (CI) will become the first U.S. health insurer to require genetic counseling nationwide before it pays for tests for hereditary breast and ovarian cancer, a move that may threaten sales for Myriad Genetics Inc. (MYGN) The policy affects tests for the BRCA1 and BRCA2 genes, the most common cause of hereditary breast cancer, as well as genes for hereditary colon cancer and a heart abnormality called long QT syndrome, David Finley, a national medical officer for the Bloomfield, Connecticut-based insurer, said in an Aug. 16 interview. It takes effect Sept. 16.
Help employers find you! Check out all the jobs and post your resume.
comments powered by